Screener
Edgewise Therapeutics, Inc. EWTX Investing Cash Flow
Investing Cash Flow at other companies
Other financials
Where this comes from
Reported directly by Edgewise Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInInvestingActivities.
The source filing: Edgewise Therapeutics, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 8:09 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001104659-26-056713
| Line item | Three months ended March 31, 2026 | Three months ended March 31, 2025 |
|---|---|---|
| Sales of marketable securities | 3,966 | 15,000 |
| Maturities of marketable securities | 108,879 | 151,122 |
| Purchases of property and equipment | (260) | (44) |
| Net cash provided by investing activities | 2,433 | 43,898 |
| Cash flows from financing activities | ||
| Exercise of stock options | 12,173 | 2,261 |
| Payment of deferred offering costs | — | (38) |
| Net cash provided by financing activities | 12,173 | 2,223 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Edgewise Therapeutics, Inc.'s investing cash flow?
- Edgewise Therapeutics, Inc. (EWTX) reported investing cash flow of $2.43M in Q1 2026.
- How has Edgewise Therapeutics, Inc.'s investing cash flow changed year-over-year?
- Edgewise Therapeutics, Inc.'s investing cash flow decreased by 94.5% year-over-year, from $43.9M to $2.43M.
- What does investing cash flow mean?
- Total net cash provided by or used in investing activities — capex, acquisitions, investment purchases/sales, and other investing items.
Ask your AI about Edgewise Therapeutics, Inc.'s investing cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude